Prof. Dr. Markus Pietsch

Dr. rer. nat.
Prof. Dr. Markus Pietsch

Campus Leverkusen
Campusplatz 1
51379 Leverkusen
Room 2121 Mailing address

  • Phone: +49 214-32831-4605

Office hours

Consultation hour by agreement

Campus Leverkusen, Room 2121
Please contact me via email for an appointment. The meeting will take place in my office or via Zoom. Zoom: Meeting-ID: 693 9393 3601 Kenncode: 004294

Teaching disciplines

  • Biochemistry and Bioanalytics
  • Bio-Pharmaceutical Chemistry / Pharmacology

Research fields

  • Development, validation and optimization of assay methods to investigate disease-relevant enzymes and protein-protein interactions
  • Expression and purification of target proteins from prokaryotic and eukaryotic cells and from human tissues
  • Screening of compound libraries, molecular characterization of target-ligand interactions, investigations on structure-activity relationships
  • Interaction of small molecule ligands with therapeutically relevant proteins
    Center of Pharmacology, University Hospital of Cologne
  • Photodecarboxylative ring annulation of α- and β-functionalized phthaloyl-GABA derivatives: bioactive pyrroloisoindolinones with high quantum efficiency
    Schulze, W.; Zimmer, A.; Neudörfl, J.-M.; Dato, F. M.; Sommerfeld, P.; Pietsch, M.; Derondeau, H.; Gaida, F.; Riedle, E.; Griesbeck, A. G., ChemPhotoChem 2024, e202400033, doi: 10.1002/cptc.202400033. Online ahead of print.
  • In-depth analysis of Gαs protein activity by probing different fluorescently labeled guanine nucleotides
    Pepanian, A.; Sommerfeld, P.; Binbay, F. A.; Fischer, D.; Pietsch, M.; Imhof D., Biol. Chem. 2024, 405, 297-309, doi: 10.1515/hsz-2023-0321.
  • Synthesis and evaluation of radioiodinated estrogens for diagnosis and therapy of male urogenital tumours.
    Braun, F.; Jaschinski, M.; Täger, P.; Marmann, V.; von Brandenstein, M.; Köditz, B.; Fischer, T.; Muñoz-Vázquez, S.; Zimmermanns, B.; Dietlein, M.; Sudbrock, F.; Krapf, P.; Fischer, D.; Heidenreich, A.; Drzezga, A.; Kirsch, S.; Pietsch, M.; Schomäcker, K., Org. Biomol. Chem. 2023, 21, 3090-3095, doi: 10.1039/d3ob00114h.
  • The impact of Nε-acryloyllysine piperazides on the conformational dynamics of transglutaminase 2.
    Heerwig, A.;# Kick, A.; Sommerfeld P.; # Eimermacher, S.; Hartung, F.; Laube, M.; Fischer, D.; Pietzsch, H.-J.; Pietzsch, J.; Löser, R.; Mertig, M.; Pietsch, M.; Wodtke, R., Int. J. Mol. Sci. 2023, 24:1650. doi: 10.3390/ijms24021650.
    # Authors contributed equally to this work.
  • Fluorescence anisotropy assay with guanine nucleotides provides access to functional analysis of Gαi1 proteins.
    Pepanian, A.;# Sommerfeld, P.;# Kasprzyk, R;# Kühl, T.; Binbay, F. A.; Hauser, C.; Löser, R.; Wodtke, R.; Bednarczyk, M.; Chrominski, M.; Kowalska, J.; Jemielity, J.; Imhof, D.; Pietsch, M., Anal. Chem. 2022, 94, 14410-14418. doi: 10.1021/acs.analchem.2c03176.
    4th Cover of the issue:
  • Application of a fluorescence anisotropy-based assay to quantify transglutaminase 2 activity in cell lysates.
    Hauser, S.; Sommerfeld, P.; Wodtke, J.; Hauser, C.; Schlitterlau, P.; Pietzsch, J.; Löser, R.;# Pietsch, M.;#, Wodtke, R.#, Int. J. Mol. Sci. 2022, 23:4475, doi: 10.3390/ijms23094475.
    # Authors contributed equally to this work.
  • Angiotensin II type 1 receptor localizes at the blood-bile barrier in humans and pigs.
    Pryymachuk, G.; El-Awaad, E.; Piekarek, N.; Drebber, U.; Maul, A. C.; Hescheler, J.; Wodarz, A.; Pfitzer, G.; Neiss, W. F.; Pietsch, M.; Schroeter, M. M., Histochem. Cell Biol. 2022, 157, 513-524, doi: 10.1007/s00418-022-02087-z.
  • 2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors.
    Schäkel, L.; Mirza, S.; Pietsch, M.; Lee, S.-Y.; Keuler, T.; Sylvester, K.; Pelletier, J.; Sévigny, J.; Pillaiyar, T.; Namasivayam, V.; Gütschow, M.; Müller C. E., Arch. Pharm. (Weinheim) 2021, 354:e2100300, doi: 10.1002/ardp.202100300.
  • Development of an 18F-labeled irreversible inhibitor of transglutaminase 2 as radiometric tool for quantitative expression profiling in cells and tissues.
    Wodtke, R.: Wodtke, J.; Hauser, S.; Laube, M.; Bauer, D.; Rothe, R.; Neuber, C.; Pietsch, M.; Kopka, K.; Pietzsch, J. Löser, R., J. Med. Chem. 2021, 64, 3462-3478, doi: 10.1021/acs.jmedchem.1c00096.
  • Distinct 3-disulfide-bonded isomers of tridegin differentially inhibit coagulation factor XIIIa: The influence of structural stability on bioactivity.
    Bäuml, C. A.; Paul George, A. A.; Schmitz, T.; Sommerfeld, P.; Pietsch, M.; Podsiadlowski, L.; Steinmetzer, T.; Biswas, A.; Imhof, D., Eur. J. Med. Chem. 2020, 201:112474, doi: 10.1016/j.ejmech.2020.112474.
  • Synthesis and SAR of tetracyclic inhibitors of protein kinase CK2 derived from furocarbazole W16.
    Kröger, L.; Daniliuc, C. G.; Ensan, D.; Borgert, S.; Nienberg, C.; Lauwers, M.; Steinkrüger, M.; Jose, J.; Pietsch, M.; Wünsch, B., ChemMedChem 2020, 15, 871-881, doi: 10.1002/cmdc.202000040.
  • Solution-phase synthesis of the fluorogenic TGase 2 acyl donor Z-Glu(HMC)-Gly-OH and its use for inhibitor and amine substrate characterization.
    Wodtke, R.; Pietsch, M.; Löser, R., Anal. Biochem. 2020, 595:113612, doi: 10.1016/j.ab.2020.113612.
  • Unexpected CK2β-antagonistic functionality of bisubstrate inhibitors targeting protein kinase CK2.
    Pietsch, M.; Viht, K.; Schnitzler, A.; Ekambaram, R.; Steinkrüger, M.; Enkvist, E.; Nienberg, C.; Nickelsen, A.; Lauwers, M.; Jose, J.; Uri, A.; Niefind, K., Bioorg. Chem. 2020, 96:103608, doi: 10.1016/j.bioorg.2020.103608.
  • ω-Quinazolinonylalkyl aryl ureas as reversible inhibitors of monoacylglycerol lipase.
    Dato, F. M.; Neudörfl, J. M.; Gütschow, M.; Goldfuss, B.; Pietsch, M., Bioorg. Chem. 2020, 94:103352, doi: 10.1016/j.bioorg.2019.103352.
  • Direct, gabapentin-insensitive interaction of a soluble form of the calcium channel subunit α2δ-1 with thrombospondin-4.
    El-Awaad, E.; Pryymachuk, G.; Fried, C.; Matthes, J.; Isensee, J.; Hucho, T.; Neiss, W. F.; Paulsson, M.; Herzig, S.; Zaucke, F.; Pietsch, M., Sci. Rep. 2019, 9:16272, doi: 10.1038/s41598-019-52655-y.
  • Chromenones as Multineurotargeting Inhibitors of Human Enzymes.
    Lemke, C.; Christmann, J.; Yin, J.; Alonso, J. M.; Serrano, E.; Chioua, M.; Ismaili, L.; Martínez-Grau, M. A.; Beadle, C. D.; Vetman, T.; Dato, F. M.; Bartz, U.; Elsinghorst, P. W.; Pietsch, M.; Müller, C.E.; Iriepa, I.; Wille, T.; et al., ACS Omega 2019, 4, 22161-22168, doi: 10.1021/acsomega.9b03409.
  • AMD-associated HTRA1 variants do not influence TGF-β signaling in microglia. In: Bowes Rickman, C.; Grimm, C.; Anderson, R.; Ash, J.; LaVail, M.; Hollyfield, J. (eds) Retinal Degenerative Diseases.
    Akhtar-Schaefer, I.; Reuten, R.; Koch, M.; Pietsch, M.; Langmann, T., Adv. Exp. Med. Biol. 2019, 1185, 3-7, doi: 10.1007/978-3-030-27378-1_1.
  • Design of CK2β-mimicking peptides as tools to study the CK2α/CK2β interaction in cancer cells.
    Lindenblatt, D.; Horn, M.; Götz, C.; Niefind, K.; Neundorf, I.; Pietsch, M., ChemMedChem 2019, 14, 833-841, doi: 10.1002/cmdc.201800786.
  • ω-Phthalimidoalkyl aryl ureas as potent and selective inhibitors of cholesterol esterase.
    Dato, F. M.; Sheikh, M.; Uhl, R. Z.; Schüller, A. W.; Steinkrüger, M.; Koch, P.; Neudörfl, J.-M.; Gütschow, M.; Goldfuß, B.; Pietsch, M., ChemMedChem 2018, 13, 1833-1847, doi: 10.1002/cmdc.201800388.
  • Crystal structure of highly glycosylated human leukocyte elastase in complex with an S2'-site binding inhibitor.
    Hochscherf, J.; Pietsch, M.; Tieu, W.; Kuan, K.; Abell, A. D.; Gütschow, M.; Niefind, K., Acta Crystallogr. F Struct. Biol. Commun. 2018, 74, 480-489, doi: 10.1107/S2053230X1800537X.
  • Nԑ-Acryloyllysine piperazides as irreversible inhibitors of transglutaminase 2: Synthesis, structure-activity relationships, and pharmacokinetic profiling.
    Wodtke, R.; Hauser, C.; Ruiz-Gómez, G.; Jäckel, E.; Bauer, D.; Lohse, M.; Wong, A.; Pufe, J.; Ludwig, F.-A.; Fischer, S.; Hauser, S.; Greif, D.; Pisabarro, M. T.; Pietzsch, J.; Pietsch, M.; Löser, R., J. Med. Chem. 2018, 61, 4528-4560, doi: 10.1021/acs.jmedchem.8b00286.
    Cover of the issue:
  • Characterization of fatty acid amide hydrolase activity by a fluorescence-based assay.
    Dato, F. M.; Maaßen, A.; Goldfuß, B.; Pietsch, M., Anal. Biochem. 2018, 546, 50-57, doi: 10.1016/j.ab.2018.01.026.
  • Assessment of inhibitory effects on major human cytochrome P450 enzymes by spasmolytics used in the treatment of overactive bladder syndrome.
    Dahlinger, D.; Aslan, S.; Pietsch, M.; Frechen, S.; Fuhr, U., Ther. Adv. Urol. 2017, 9, 163-177, doi: 10.1177/1756287217708951.
  • A fluorescence anisotropy-based assay for determining the activity of tissue transglutaminase.
    Hauser, C.;* Wodtke, R.;* Löser, R.;# Pietsch, M.#, Amino Acids 2017, 49, 567-583, doi: 10.1007/s00726-016-2192-5.
    *, # C. Hauser and R. Wodtke as well as R. Löser and M. Pietsch contributed equally to this work.
  • Synthesis and kinetic characterisation of water-soluble fluorogenic acyl donors for transglutaminase 2.
    Wodtke, R.; Schramm, G.; Pietzsch, J.; Pietsch, M.; Löser, R., ChemBioChem 2016, 17, 1263-1281. Corrigendum: ChemBioChem 2016, 17, 1674, doi: 10.1002/cbic.201600048.
  • Selective inhibitors of glutathione transferase P1 with trioxane structure as anticancer agents.
    Bräutigam, M.; Teusch, N.; Schenk, T.; Sheikh, M.; Aricioglu, R. Z.; Borowski, S. H.; Neudörfl, J.-M.; Baumann, U.; Griesbeck, A. G.; Pietsch M., ChemMedChem 2015, 10, 629-63, doi: 10.1002/cmdc.201402553.
    Back cover of the issue:
  • Activated microglia/macrophage whey acidic protein (AMWAP) inhibits NFκB signaling and induces a neuroprotective phenotype in microglia.
    Aslanidis, A.; Karlstetter, M.; Scholz, R.; Fauser, S.; Neumann, H.; Fried, C.; Pietsch, M.;# Langmann, T.#, J. Neuroinflammation 2015, 12:77, doi: 10.1186/s12974-015-0296-6.
    # Authors contributed equally to this work.
  • Model studies on peroxidic glutathione transferase (GST) inhibitors: C5-methylated 1,2,4-trioxanes with C6-acrylate side chains.
    Griesbeck, A. G.; Maaßen, A.; Bräutigam, M.; Pietsch, M., Eur. J. Org. Chem. 2015, 4349-4352, doi:10.1002/ejoc.201500326.
    Cover of the issue:
    Eur. J. Org. Chem.
  • Development of a HTS-compatible assay to identify inhibitors of the CK2a/CK2ß interaction.
    Hochscherf, J.; Lindenblatt, D.; Steinkrüger, M.; Yoo, E.; Ulucan, Ö.; Herzig, S.; Issinger, O.-G.; Helms, V.; Götz, C.; Neundorf, I.; Niefind, K.; Pietsch, M., Anal. Biochem. 2015, 468, 4-14, doi: 10.1016/j.ab.2014.09.003.
  • Macrocyclic protease inhibitors with reduced peptide character.
    Chua, K. C.; Pietsch, M.; Zhang, X.; Hautmann, S.; Chan, H. Y.; Bruning, J. B.; Gütschow, M.; Abell, A.D., Angew. Chem. 2014, 126, 7962-7965; Angew. Chem. Int. Ed. 2014, 53, 7828-7831, doi: 10.1002/anie.201404301.
  • Tissue transglutaminase: an emerging target for therapy and imaging.
    Pietsch, M.; Wodtke, R.; Pietzsch, J.; Löser, R., Bioorg. Med. Chem. Lett. 2013, 23, 6528-6543, doi: 10.1016/j.bmcl.2013.09.060.
  • Regioselective sulfonylation and N- to O-sulfonyl migration of quinazolin-4(3H)-ones and analogous thienopyrimidin-4(3H)-ones.
    Mertens, M. D.; Pietsch, M.; Schnakenburg, G.; Gütschow, G., J. Org. Chem. 2013, 78, 8966-8979, doi: 10.1021/jo4010876.
  • Synthesis and extended activity of triazole-containing macrocyclic protease inhibitors.
    Pehere, A. D.; Pietsch, M.; Gütschow, M.; Neilsen, P. M.; Callen, D. F.; Pedersen, D. S.; Nguyen, S.; Sykes, M. J.; Zvarec, O.; Abell, A. D., Chem. Eur. J. 2013, 19, 7975-7981, doi: 10.1002/chem.201204260.
  • First structure of protein kinase CK2 catalytic subunit with an effective CK2β-competitive ligand.
    Raaf, J.; Guerra, B.; Neundorf, I.; Bopp, B.; Issinger, O.-G.; Jose, J.; Pietsch, M.; Niefind, K., ACS Chem. Biol. 2013, 8, 901-907, doi: 10.1021/cb3007133.
  • New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds.
    Heng, S.; Tieu, W.; Hautmann, S.; Kuan, K.; Pedersen, D. S.; Pietsch, M.; Gütschow, M.; Abell, A. D., Bioorg. Med. Chem. 2011, 19, 7453-7463, doi: 10.1016/j.bmc.2011.10.042.
  • Fluorinated β2- and β3-amino acids: synthesis and inhibition of α-chymotrypsin.
    Peddie, V.;# Pietsch, M.;# Bromfield, K. M.; Pike, R. N.; Duggan, P. J.; Abell, A. D., Synthesis 2010, 1845-1859, doi: 10.1055/s-0029-1218743.
    # Authors contributed equally to this work.
  • Calpains: attractive targets for the development of synthetic inhibitors.
    Pietsch, M.; Chua, K. C. H.; Abell, A. D., Curr. Top. Med. Chem. 2010, 10, 270-293, doi: 10.2174/156802610790725489.
  • Isopropylammonium tetrafluorohydrogenphthalate: structural characterization and comparison to two related salts with different stoichiometric ratios.
    Häcker, H.-G.; Schnakenburg, G.; Hoffbauer, W.; Daniels, J.; Pietsch, M.; Gütschow, M., J. Mol. Struct. 2009, 934, 23-27, doi: 10.1016/j.molstruc.2009.06.013.
    J. Mol. Struct.
  • Kinetics of inhibition of acetylcholinesterase in the presence of acetonitrile.
    Pietsch, M.; Christian, L.; Inhester, T.; Petzold, S.; Gütschow, M., FEBS J. 2009, 276, 2292-2307, doi: 10.1111/j.1742-4658.2009.06957.x.
  • Multiple ligands in opioid research.
    Ballet, S.; Pietsch, M.; Abell, A. D., Protein Pept. Lett. 2008, 15, 668-682, doi: 10.2174/092986608785133672.
  • Structural characterization of two salts derived from tetrafluorophthalic acid and isopropylamine.
    Pietsch, M.; Häcker, H.-G.; Schnakenburg, G.; Hoffbauer, W.; Nieger, M.; Gütschow, M., J. Mol. Struct. 2008, 878, 131-138, doi: 10.1016/j.molstruc.2007.07.044.
    J. Mol. Struct.
  • N-Benzyltetrahydropyrido-anellated thiophene derivatives: new anticholinesterases.
    Pietsch, M.; Nieger, M.; Gütschow, M., Acta Cryst. 2007, C63, o147-o151, doi: 10.1107/S0108270107001461.
  • Compatible solutes as protectants for zymogens against proteolysis.
    Kolp, S.; Pietsch, M.; Galinski, E. A.; Gütschow, M., Biochim. Biophys. Acta 2006, 1764, 1234-1242, doi: 10.1016/j.bbapap.2006.04.015.
  • Synthesis of tricyclic 1,3-oxazin-4-ones and kinetic analysis of cholesterol esterase and acetylcholinesterase inhibition.
    Pietsch, M.; Gütschow, M., J. Med. Chem. 2005, 48, 8270-8288, doi: 10.1021/jm0508639.
  • 2,4,5-Triphenylisothiazol-3(2H)-one 1,1-dioxides as inhibitors of human leukocyte elastase
    Gütschow, M.; Pietsch, M.; Themann, A.; Fahrig, J.; Schulze, B., J. Enzyme Inhib. Med. Chem. 2005, 20, 341-347, doi: 10.1080/14756360500148783.
  • Cholesterol esterase action on human high density lipoproteins and inhibition studies: detection by MALDI-TOF MS.
    Zschörnig, O.; Pietsch, M.; Süß, R.; Schiller, J.; Gütschow, M., J. Lipid Res. 2005, 46, 803-811, doi: 10.1194/jlr.M400265-JLR200.
  • Synthesis of 2-phenylisothiazol-3(2H)-one 1,1 dioxides: inhibitors of human leukocyte elastase.
    Gütschow, M.; Pietsch, M.; Taubert, K.; Freysoldt, T. H. E.; Schulze, B., Z. Naturforsch. 2003, 58b, 111-120, doi: 10.1515/znb-2003-0115.
    Z. Naturforsch.
  • Alternate substrate inhibition of cholesterol esterase by thieno[2,3-d][1,3]oxazin-4-ones.
    Pietsch, M.; Gütschow, M., J. Biol. Chem. 2002, 277, 24006-24013, doi: 10.1074/jbc.M112252200.
  • Inhibition of cathepsin G by 2-amino-3,1-benzoxazin-4-ones: kinetic investigations and docking studies.
    Gütschow, M.; Kuerschner, L.; Pietsch, M.; Ambrozak, A.; Neumann, U.; Günther, R.; Hofmann, H.-J., Arch. Biochem. Biophys. 2002, 402, 180-191, doi: 10.1016/S0003-9861(02)00054-1.
  • 2-(Diethylamino)thieno[1,3]oxazin-4-ones as stable inhibitors of human leukocyte elastase.
    Gütschow, M.; Kuerschner, L.; Neumann, U.; Pietsch, M.; Löser, R.; Koglin, N.; Eger, K., J. Med. Chem. 1999, 42, 5437-5447, doi: 10.1021/jm991108w.
  • Patente / Patents
    Patents M. Pietsch
  • Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie e.V. (DGPT)
  • Rottendorf Prize 2015 in the field of Pharmacology (Rottendorf Pharma GmbH and Rottendorf Foundation) (15.10.2015)
  • DAAD (German Academic Exchange Service) Research Scholarship (07/2007 – 06/2008) (PKZ: D/06/48851)
  • Commerzbank Dissertation Award 2007 (University of Bonn, Germany) (14.12.2007)
  • PHOENIX Pharmaceutical Science Award 2003, field of Pharmaceutical Chemistry (PHOENIX Pharmahandel AG & Co KG, Mannheim, Germany) (24.10.2003)
since March 2023 Faculty of Applied Natural Sciences, University of Applied Sciences Cologne, Germany
Professor for Biological Chemistry and Drug Discovery Faculty of Applied Natural Sciences, University of Applied Sciences Cologne
since March 2010 Center of Pharmacology (previously Department of Pharmacology), University Hospital of Cologne, Germany
Project group leader and Research associate Center of Pharmacology, University Hospital of Cologne
July 2007 - February 2010 School of Chemistry and Physics (now School of Physics, Chemistry and Earth Sciences), University of Adelaide, Australia
Postdoctoral fellow (DAAD research scholarship (2007-2008), Australian Research Council Associate (2008-2010)) in the group of Professor Dr. Andrew D. Abell School of Physics, Chemistry and Earth Sciences, University of Adelaide
May 2006 - June 2007 Pharmaceutical Institute, University of Bonn, Germany
Postdoctoral fellow in the group of Professor Dr. Michael Gütschow Pharmaceutical Institute, University of Bonn
May 2001 - April 2006 Pharmaceutical Institute, University of Bonn, Germany
Research associate/doctoral student; supervisor: Professor Dr. Michael Gütschow; preparation of a dissertation about the synthesis of tricyclic 1,3-oxazin-4-ones as inhibitors of cholesterol esterase and acetylcholinesterase. 28.04.2006: Graduation as Dr. rer. nat. (same as Ph.D.) in Medicinal and Pharmaceutical Chemistry Pharmaceutical Institute, University of Bonn
October 1996 - March 2001 Institute of Biochemistry, University of Leipzig
Undergraduate studies of Biochemistry; 29.03.2001: Graduation with a Diploma in Biochemistry Institute of Biochemistry, University of Leipzig